مباشر

PharmaVoicePfizer CFO departs for consumer goods sector FierceBiotechSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease PharmaVoiceBacked by Sanofi and Roche, Orano Med chases radiopharma leadership BioWorldF2G preps NDA for first new antifungal in 20 years on solid phase III Labiotech8 of the most expensive drugs in biopharma: Unraveling the costliest medications Endpoints NewsPost-Hoc Live: Are the China hawks winning?FierceBiotechFor biopharma manufacturing at speed and scale, the future is flexible BioPharma DiveAbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs FierceBiotechDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says FierceBiotechHelmed by Sanofi vet, Bionyara emerges with $165M and three licensed I&I assets Endpoints NewsRegenxbio to resubmit Hunter syndrome gene therapy without new study Endpoints NewsDefinium reports Phase 3 hit for LSD drug in severe form of depression

Endpoints News ٢٢ يونيو ٢٠٢٦

Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration

The neurodegenerative disease-focused company Nura Bio said Monday it has secured $73.8 million in a Series B raise to fund two programs through early clinical...

The neurodegenerative disease-focused company Nura Bio said Monday it has secured $73.8 million in a Series B raise to fund two programs through early clinical trials. The cash should support Nura’s clinical work over the ...